Targeting FBXO44 by genetic knockdown or pharmacologic inhibition of SUV39H1 restrained the proliferation of breast, lung, colon, and glioblastoma cancer cells in vitro and tumor growth in immunodeficient mice. Here, SUV39H1 is linked to neoplasm.